Prevalence and risk factors for COPD in subjects with preserved ratio impaired spirometry

Rina Kanetake,1 Kazufumii Takamatsu,1 Kaechang Park,2 Akihito Yokoyama1

ABSTRACT

Background Chronic obstructive pulmonary disease (COPD) has been found to be caused by impairment of lung development. Preserved ratio impaired spirometry (PRISm) is thought to be a subtype of lung growth impairment and is associated with COPD. PRISm is heterogeneous and the prevalence and progression to COPD are not yet clear. To prove this, we examined the association by using the medical check-up data.

Methods This retrospective study included medical check-up subjects who visited the Kochi Medical Check-up Clinic at least twice for both period 1 (P1) (2014–2016) for the first visit and period 2 (P2) (2017–2019) for the final visit. The mean duration between visits was 1042±323 days. COPD was defined as a forced expiratory volume in 1 s (FEV1):forced vital capacity (FVC) ratio <lower limit of normal (LLN), and PRISm was defined as an FEV1:FVC ratio <LLN and per cent forced expiratory volume in 1 s (%FEV1) (FEV1/predicted FEV1) of <80% without bronchodilators in this study.

Results Of 1672 subjects (mean age±SD 56.5±9.5), 976 (58.4%) were male. The prevalence of PRISm was 10.5% in P1 and 8.9% in P2. The percentage of subjects who progressed to COPD was higher in PRISm than in the normal lung function group (OR 2.62, p=0.014). In logistic regression analysis, PRISm was an independent risk factor for developing COPD (OR 3.75, p<0.001). The best cut-off value of %FEV1, for prediction of progression to COPD was 86%. The proportion of the PRISm group increased (23.6%) in this cut-off.

Conclusion The prevalence of PRISm was around 10% but increased up to 23.6% at the best cut-off for progression to COPD, and careful follow-up is necessary in these groups even if FEV1/FVC is normal.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide.1–4 Death and increased medical costs due to many complications and exacerbations caused by COPD are also important problems.5–8 COPD has been mainly accepted as a self-inflicted condition caused by tobacco smoking. Recently, it has been proposed that impaired lung growth leads to COPD even if there is no rapid lung function decline.9–11

The preserved ratio impaired spirometry (PRISm) can be caused by a various factor such as childhood asthma, infections and obesity and has been proposed as the concept of low lung growth or early COPD. The PRISm is the condition of proportional decreases in forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), which result in a normal FEV1:FVC ratio. PRISm is a product of two binary variables, which increases the risk of error. Therefore, there is an opinion that PRISm is uncertain.12 Recently, PRISm has been considered as a subtype that is prone to the development of COPD or acute exacerbation, and it has been reported that 32.6% progressed to COPD in 4–5 years of observational studies.13,14 PRISm is heterogeneous, and the prevalence, sex differences and mortality of PRISm are not clear, with reports varying by region and race. Therefore, we examined the prevalence of
PRISm and risk of progression from PRISm to COPD in this study.

METHODS

Study design
A longitudinal retrospective study was conducted on 1679 health check-up subjects who visited our institution (Kochi Medical Check Clinic, Kochi, Japan) for medical check-ups at least twice between April 2014 and December 2019. First visit was during 2014–2016 defined as period 1 (P1) and final visit during 2017–2019 as period 2 (P2). Mean duration from first and final visits was 1042±323 days.

Medical information was obtained through a questionnaire which included previous and current medical history, as well as habits such as smoking, alcohol consumption, diet and exercise.

Patient and public involvement
Patients and public were not involved in this study design and planning. They would be informed of our study plan including the recruitment criteria and timing via a notice on the website of clinic because this was retrospective study. When they offered not to participate, we removed them from participation.

Spirometry
Spirometry (FVC, FEV₁ and FEV₁/FVC ratio) was performed using a spirometer (Spiroshift SP-770 COPD; Fukuda Denshi, Tokyo, Japan) in accordance with the American Thoracic Society recommendations. Spirometry was performed without the use of bronchodilators. COPD was defined as an FEV₁/FVC ratio < lower limit of normal (LLN). PRISm was defined as an FEV₁/FVC ratio > LLNand per cent forced expired volume in 1 s (%FEV₁) (FEV₁/predicted FEV₁) of <80%. The predicted values of FVC and FEV₁ were calculated according to the recommendations of the Japanese Respiratory Society.

Statistical analyses
The Quantitative data of characteristics were presented as mean±SD. Multiple linear regression analysis was performed to determine the factors that contributed to progression of COPD. The explanatory variables were age, gender, body mass index (BMI), smoking history and the presence of PRISm. The cut-off of %FEV₁ that progresses to COPD was examined by the receiver operating characteristic (ROC) curve. Missing values were excluded. A p value of <0.05 was considered significant.

RESULTS

Prevalence and characteristics of each group in P1
The prevalence of PRISm was 10.5% in P1 and 8.9% in P2, respectively.

The characteristics of subjects with PRISm, COPD and normal spirometry in P1 are shown in table 1.

| Subject characteristics | Period 1 (2014–2016) |
|-------------------------|----------------------|
|                        | Normal | PRISm | COPD |
| Subjects, n             | 1409   | 176   | 87   |
| Age (years)*            | 56.1±9.5 | 60.1±9.2 | 56.3±9.2 |
| Male sex (%)            | 805 (57.1%) | 112 (63.6%) | 59 (67.8%) |
| BMI (kg/m²)*            | 23.6±3.4 | 23.9±4.6 | 22.7±2.9 |
| Current smoker, n (%)   | 207 (14.7) | 42 (23.9) | 23 (26.4) |
| Former smoker, n (%)    | 386 (27.4) | 53 (30.1) | 31 (35.6) |
| Never-smoker, n (%)     | 816 (57.9) | 81 (46.0) | 33 (37.9) |
| FEV₁ (litre)*           | 2.70±0.62 | 2.03±0.44 | 2.31±0.67 |
| FVC (litre)*            | 3.32±0.78 | 2.61±0.60 | 3.41±0.94 |
| FEV₁/FVC (%)*           | 81.4±5.0 | 78.4±5.6 | 67.6±3.6 |
| %FEV₁ (%)*              | 96.8±10.0 | 73.1±7.2 | 78.4±16.2 |
| %FVC (%)*               | 95.0±10.3 | 74.0±8.4 | 92.2±18.8 |
| Drinking habit           |        |       |      |
| Everyday                | 454 (32.2) | 75 (42.6) | 34 (39.1) |
| Sometime                | 594 (42.5) | 47 (26.7) | 34 (39.1) |
| Never                   | 361 (25.6) | 54 (30.7) | 19 (21.8) |

*Values are given as mean±SD or number (%). BMI, body mass index; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; PRISm, preserved ratio impaired spirometry.

The average age of the subjects was 56.5±9.5 in P1. The number of men was 976 (58.3%). The smoking history was more in the order of COPD, PRISm and normal group. BMI of women tended to be lower than men. The proportion of non-smokers was significantly higher in women (588 subjects, 84.5%) than in men (342 subjects, 35%). The proportion of PRISm in P1 was 11.5% in men and 9.2% in women, with no significant sex-specific difference.

Transition from P1 to P2 of each group
Transition from P1 to P2 of each group is shown in figure 1. In the normal lung function group in P1, 25 subjects (1.8%) progressed to COPD in P2, whereas in the PRISm group, 11 subjects (6.3%) progressed to COPD, in which incidence was significantly higher.

Logistic regression analysis on the risk of progressing to COPD
The risk of developing COPD in P2 from normal lung function group and PRISm in P1 was examined by logistic regression analysis (table 2). The explanatory variables were age, sex, BMI, smoking history and presence of PRISm. It was found that low BMI and PRISm are independent risk factors that progress to COPD (OR 4.58, 95% CI 2.22 to 9.40, p<0.001). It analysed for sex-specific differences, PRISm was a risk factor for developing COPD in men (p<0.05) but not in women (p=0.787, date not shown).

Table 1 Subject characteristics
In previous reports, PRISm was defined as %FEV$_1$ less than 80%, and that definition was used in this study. However, the rationale for setting %FEV$_1$ to 80% in PRISm is not clear. The best cut-off of %FEV$_1$ for progression to COPD was investigated using ROC curve (figure 2). The sensitivity and specificity were best when %FEV$_1$ was 86% (area under the curve=0.706, 95% CI 0.617 to 0.794). If this is used, the proportion of the normal group, PRISm group or COPD group is in P1 and P2, as shown in figure 3. The proportion of the PRISm group increased (23.6%). Logistics regression analysis for the risk for progress from PRISm to COPD showed that low BMI, smoking history and PRISm were significant risk factors (model 2, table 2).

**DISCUSSION**
This study demonstrated that the prevalence of PRISm in Japan is around 10%, and the PRISm is an independent risk factor for COPD progression. The most predictable cut-off value of %FEV$_1$ to develop to COPD was 86%. This finding may indicate that if %FEV$_1$ is <86%, there is a risk of COPD progression and careful follow-up is necessary.

The prevalence of PRISm was 12.4%–12.5% in the COPD gene study, 5.3%–7.0% in the Rotterdam study and 11.7% in the other study.13 14 17  The difference in prevalence of PRISm may be due to background differences such as age, BMI and smoking history, but it is around 10% in all studies, which is similar to our study. The COPD gene study and the study from Korea included smokers only. In the Rotterdam study, the average age

---

**Table 2** Logistic regression analysis on the risk of progression to COPD

|                | Model 1 |               | Model 2 |               |
|----------------|---------|---------------|---------|---------------|
|                | OR      | 95% CI        | P value | OR            | 95% CI        | P value |
| Female*        | 0.63    | 0.26 to 1.51  | 0.3     | 0.61          | 0.27 to 1.38  | 0.23    |
| Age            | 0.98    | 0.95 to 1.02  | 0.28    | 0.99          | 0.95 to 1.02  | 0.47    |
| BMI            | 0.88    | 0.79 to 0.98  | 0.024   | 0.88          | 0.79 to 0.98  | 0.015   |
| Ever smoker †  | 1.69    | 1.76 to 3.76  | 0.19    | 2.48          | 1.16 to 5.34  | 0.019   |
| PRISm          | 3.75    | 1.78 to 7.97  | <0.001  | 4.07          | 2.06 to 8.07  | <0.001  |

Model 1: PRISm defined as FEV$_1$/FVC >70%, %FEV$_1$ >80%
Model 2: PRISm defined as FEV$_1$/FVC >70%, %FEV$_1$ >86%
*Risk of women developing COPD for men.
†Risk of current smoker and former smoker developing COPD for never-smoker.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV$_1$, forced expiratory volume in 1 s; FVC, forced vital capacity; PRISm, preserved ratio impaired spirometry.

---

**Figure 2** Receiver operating characteristic curve for progression from PRISm to COPD. The %FEV$_1$, cut-off for progression to COPD in subjects with a 1 s rate of 70% or greater (normal lung function group and PRISm). AUC, area under the curve; COPD, chronic obstructive pulmonary disease; FEV$_1$, forced expiratory volume in 1 s; %FEV$_1$, per cent forced expiratory volume in 1 s PRISm, preserved ratio impaired spirometry.

**Figure 3** Transitions of lung function categories as the cut-off %FEV$_1$ is set to 86% between period 1 and period 2. COPD, chronic obstructive pulmonary disease; %FEV$_1$, per cent forced expiratory volume in 1 s PRISm, preserved ratio impaired spirometry.
of the subjects was around 70 years old, which was older than those in the other studies. BMI was higher in the Rotterdam and COPD gene studies than in our study. The value of FVC could be reduced by obesity. Although subjects with PRISm (low FVC) in Europe and the USA are influenced by obesity, those with PRISm in our study may suggest more likely to be due to lung growth impairments.

PRISm is considered as a subtype that is more likely to progress to COPD. In our study, the transition from PRISM to COPD was also significantly higher than in the normal lung function group, but the incidence was clearly lower than that in the Rotterdam or COPD gene studies. We believe that this is largely due to differences in patient background, such as smoking history, age and race. Patients with COPD in Europe and the USA tend to be obese and non-employers, whereas emphysematous and lean type are more common in East Asia. In our study, multivariate analysis showed that low BMI is a risk for progression to COPD, which is still controversial.

There are several limitations in our study. There were subjects with COPD at P1 who transitioned to PRISm or normal lung function at P2. In this study, the history of asthma and the history of treatment by bronchodilators could not be obtained. Therefore, it is possible that some of the subjects improved with bronchodilators. Because of the variability of symptoms in patients with bronchial asthma, pulmonary function tests may improve without therapeutic intervention. Impaired lung growth such as PRISm can be caused by bronchial asthma in childhood. However, it is difficult to completely exclude asthma in cohort studies. Second, it was performed by pulmonary function tests without bronchodilators in this study. The values of postbronchodilator spirometry are necessary to diagnose COPD. In this study, we recruited subjects who visited the clinic for medical check-up; thus, bronchodilators could not be used. Lastly, there may be survivor bias. This study retrospectively included those who were able to perform pulmonary function tests at both P1 and P2. Those who died were not included, and the annual decline in lung function may have been estimated to be lower than previously reported.

In conclusion, it was revealed that subjects with low %FEV₁ are a subtype that is more likely to progress to COPD, even if FEV₁/FVC is preserved. Subjects with low %FEV₁, even if FEV₁/FVC is maintained, need to be aware of the risk of progression to COPD.

Acknowledgements The authors thank T Motoki and the staff of the Kochi Medical Checkup Clinic for the support and data input.

Contributors Conceptualization: KT and AI. Data curation: KP, RK and KT. Analysis: RK and KT. Writing—original draft: RK and KT. Writing—review and editing: KT and AK. Guarantor: all authors contributed to the analysis and interpretation of data and review of the manuscript and agreed on the journal to which the manuscript will be submitted.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the ethics committee of Kochi Medical School (number 31–02, 15 August 2019). Because of retrospective study, subject consent was based on opt-out. Those who refused to participate in the study by opt-out were excluded.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. Not applicable.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Global, GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1736–88.
2. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet 2017;389:1931–40.
3. Soriano JB, Lamprecht B. Chronic obstructive pulmonary disease: a worldwide problem. Med Clin North Am 2012;96:671–80.
4. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev 2009;18:213–21.
5. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respir Med 2016;114–15.
6. Putcha N, Drummond MB, Wise RA, et al. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med 2015;36:575–91.
7. Negewo NA, Gibson PG, McDonald VM. Copd and its comorbidities: impact, measurement and mechanisms. Respirology 2015;20:1160–71.
8. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014;9:871–88.
9. Lange P, Celi B, Agusti A, et al. Lung-Function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015;373:111–22.
10. Celi BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med 2019;381:1257–66.
11. McGeachie MJ, Yarte KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med 2016;374:1842–52.
12. Knox-Brown B, Amaral AF, Burney P. Concerns about prism. Lancet Respir Med 2022;10:651–2.
13. Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam study. Eur Respir J 2020;55:1901217.
14. Wan ES, Fortis S, Flegan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med 2018;198:397–405.
15. Standardization of spirometry, American Thoracic Society. Am J Respir Crit Care Med 1994;1995;101–36.
16. Kubota M, Kobayashi H, Quanjer PH, et al. Reference values for spirometry, including lung capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir Investig 2014;52:242–50.
17. Park HJ, Byun MK, Rhee CK, et al. Significant predictors of medically diagnosed chronic obstructive pulmonary disease in patients with preserved ratio impaired spirometry: a 3-year cohort study. Respir Res 2018;19:185.
18. Peralta GP, Marcon A, Carsin A-E, et al. Body mass index and weight change are associated with adult lung function trajectories: the prospective ECRHS study. Thorax 2020;75:313–20.
19. Melton MS, Monroe HE, Qi W, et al. Effect of Interscalene brachial plexus block on the pulmonary function of obese patients: a prospective, observational cohort study. Anesth Analg 2017;125:313–9.
20. Chen Y, Horne SL, Dosman JA. Body weight and weight gain related to pulmonary function decline in adults: a six year follow up study. Thorax 1993;48:375–80.